Upadacitinib

Overview

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 ( JAK1 ) inhibitor ( IC 50 =43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Pain | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > JAK

Product Information

• Catalog No.: HY-19569
• CAS No.: 1310726-60-3
• Molecular Formula: C17H19F3N6O
• Molecular Weight: 380.37
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.75 mg/mL (7.23 mM); Clear solution
• Availability: In-stock

Source

Original product source